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Abstract 
Purpose. miR-26a-5p is a tumor suppressor (TS) miRNA often downregulated in several tumor tissues 
and tumor cell lines. In this work, we performed the re-expression of the miR-26a-5p in DU-145 
prostate cancer cells to collect genes interacting with miR-26a-5p and analyzed their integration in the 
tumorigenesis related pathways.  
Methods. The transfection of DU-145 prostate cancer cells with miR-26a-5p was done using 
nucleofection. The biological effects induced by miR-26a-5p re-expression were detected with routine 
assays for cell proliferation, cell cycle, survival, apoptosis and cell migration. The miRNA pull out 
technique was used to collect and next generation sequencing to identify the complete repertoire of the 
miR-26a-5p targets (miR-26a-5p/targetome). TargetScan 7, PITA and RNA22 were used to find the 
predicted miR-26a-5p targets in the miR-26a-5p/targetome. Gene set enrichment analysis were used to 
integrate target genes in KEGG pathways and Protein-Protein Interaction networks (PPINs) and 
modules were built.  
Results. miR-26a-5p exerted an anti-proliferative effect acting at several levels, by decreasing survival 
and migration and inducing both cell cycle block and apoptosis. The analysis of the 
miR-26a-5p/targetome showed that 1423 (1352 coding and 71 non-coding) transcripts interacted with 
miR-26a-5p. Filtering the miR-26a-5p/targetome with prediction algorithms, 628 out of 1353 transcripts 
were miR-26a-5p predicted targets and 73 of them were already validated miR-26a-5p targets. Finally, 
miR-26a-5p targets were involved in 22 KEGG pathways and 20 significant protein-protein interaction 
modules  
Conclusion. The TS-miR-26a-5p/targetome is a platform that shows both unknown and known 
miRNA/target interactions thus offering the possibility to validate genes and discover pathways in which 
these genes could be involved. 
Key words: re-expression of miR-26a-5p; DU-145 prostate cancer cells, miRNA pull out assay; next generation 
sequencing; miR-26a-5p/targetome; pathway in cancer. 
Introduction 
The miR-26a-5p is a tumor suppressor (TS) 
miRNA often downregulated in tumor tissues as well 
as in tumor cell lines [1-5]. In prostate cancer cells, the 
loss of the miR-26a-5p increased proliferation, 
migratory capacity and invasiveness [6]. Conversely, 
the re-expression of miR-26a-5p in the 
androgen-independent PC3 tumor cell line rescued 
the TS activity by directly repressing wnt5a and 
inhibiting cell proliferation [7]. Similarly, the 
miR-26a-5p re-expression in the PC3 cells repressed 
the LARP protein-1 by inhibiting the invasive 
capability of the cells [3] or blocking the G1/S 
transition by targeting the cell cycle regulating 
network [8]. Interestingly, the re-expression of 
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miR-26a-5p (miRNA replacement) in a murine model 
of hepatocellular carcinoma reduced the tumor mass 
formation in the liver [9]. Altogether, these data 
strongly support the hypothesis that the tumor 
suppressor activity of miR-26a-5p is linked to its 
capability to repress genes involved in cancer. Since a 
single miRNA targets hundreds of genes 
simultaneously, it is conceivable that as more 
interactions miR-26a-5p/mRNAs are uncovered the 
easier it will be to identify the pathways affected by its 
tumor suppressor activity. In this work, we proposed 
a way to accelerate the 'knowledge’ of 
miR-26a-5p/mRNAs interactions. Several protocols 
based on Ago immunoprecipitation (Ago-HITS-CLIP 
[10], Ago-PAR-CLIP [11], Ago-iPAR-CLIP [12], 
CLASH [13]) and the miRNA pull out assay [14] are 
appropriate to capture the miRNA/targets 
interactions. We exploited the miRNA pull out assay 
to capture and next generation sequencing (NGS) to 
identify the RNA transcripts specifically interacting 
with miR-26a-5p. We identified the transcripts 
specifically captured by miR-26a-5p 
(miR-26a-5p/targetome) and verified which of them 
were miR-26a-5p putative targets based on the 
prediction of specific algorithms. We also reported the 
procedures adopted to validate the 
miR-26a-5p/targetome and the bioinformatics 
analysis performed to highlight the pathways in 
which the target genes could be involved. 
Materials and Methods 
Cells and culture conditions 
DU-145, 22Rv1, LNCaP prostate cancer cells 
were grew in RPMI Medium 1640 (EuroClone). PC3 
prostate cancer cells grown in HAM’s medium 
(Euroclone). The medium was added with 10% FBS 
(Fetal Bovine Serum, EuroClone), 1% 
penicillin/streptomycin (2mm, EuroClone) and 1% 
L-glutamine (2mM, Sigma-Aldrich). The cells were 
incubated at 37°C in a humidified atmosphere 
containing 5% CO2. The HCT116 Dicer-/- cell line, 
which grown in McCOY’s medium (Euroclone), was 
used to perform the luciferase assay. 
Transfection 
Transient transfections of double stranded 
miRNAs mimics (miR-26a-5p) or negative control 
(miR-CT) (GenePharma) and siRNA pool against 
BIRC5 (siR-BIRC5) or negative control pool (siR-CT) 
(OriGen) of DU-145 cells were carried out using 
Amaxa Nucleofector®Device program 0-006 and 
Nucleofector®Solution L (Lonza). For each 
transfection, 1x106 of exponentially growing DU-145 
cells were suspended in 100 µl of (solution L + 
supplement) mix and then the miRNA 
mimics/siRNA was added to a final concentration of 
60 nM. After electroporation, 400 µl of RPMI medium 
were added and samples of 1x105 cells were seeded in 
culture dishes of 30 mm diameter (P30). The 
lipofectamine-mediated transfection was performed 
as following: 1.5x105 cells were seeded in P30 dishes 
and 48 hours after seeding cells were transfected with 
miRNA mimic/siRNA using 10µl of Lipofectamine 
2000 (Thermo Fisher), according to the protocol 
provided by the manufacturer. The suspension of 
transfected cells was used for cellular and molecular 
assays. 
Cell proliferation 
1×105 cells were seeded in a series of 30 mm 
diameter dish and grown for 96 hours. At 24 hours 
intervals cells were collected and counted. 
 Cell cycle analysis 
Cell cycle analysis was performed as following: 
5x105 cells were fixed with 95% cold ethanol and 
marked with 300 µl of a solution 50 µl/ml propidium 
iodide (Sigma-Aldrich). After overnight incubation at 
4°C, the cell cycle analysis was performed with Accuri 
C6 flow cytometer (BD Biosciences). Using specific 
software supplied with the instrument, the percentage 
of cells in each phase of the cell cycle was determined 
for each sample, considering the parameters 
SSC-H/FL2-A. 
Survival assay 
Cell survival was measured as following: cells 
were collected and seeded at cell density of 200 
cells/60 mm diameter culture dish to allow colony 
formation. After 10-12 days, dishes were stained with 
0.1 % CV and the ratio (number colonies/number 
seeded cells) was used to calculate the fraction of 
surviving cells. 
Apoptosis assay 
The apoptosis was measured as follows: 1x106 
cells were suspended in 300 µl Binding Buffer 1X and 
left at room temperature for 15 minutes. Thereafter, 
cell labelling was done according to the kit Annexin 
V-FITC (Sigma). Cells were then passed through flow 
cytometer Accuri C6 (BD Bioscences) and analyzed 
using FL3-H/FL1-H parameters.  
Cell migration assay 
Cell migration was measured as follows: 2x105 
cells were seeded on a plate using culture insert 
(IBIDI, Martinsried, Germany). The septum was 
removed when 80% of cell confluence was reached (0 
hour), leaving the cells free to migrate according to 
their ability and to fill the empty space. The cells were 
observed with 10x and 20x objective lenses and 
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images were captured using Leica DM IL LED 
microscope at 6, 9 and 13 hours after the removal of 
the septum and analyzed with ImageJ. The migratory 
rate of each sample was determined as the relative 
percentage of gap closure at 13 hour compared to 0 
hour. 
miRNA pull out assay 
The miRNA pull out assay was performed 
modifying the protocol described by Orom et al. [14]. 
DU-145 cells were seeded into the wells of a 6-well 
plate at the density of 1.5 x105. After 24 hours after 
seeding, cells were transfected using Lipofectamine 
2000 (Thermo Fisher) with 60nM of either miR-26a-5p 
duplex (ds-miR-26aCT) or a mix of 3’ biotin-tagged 
miR-26a-5p 7tU (nucleotide 7 was a thiouridine) and 
miR-26a-5p 17tU duplexes (ds-miR-26aBIO). The day 
after transfection, the cells were washed with PBS and 
irradiated with UV (365nm, 2J/cm2) using the 
Bio-Link crosslinking (BLX) (Ambrose Lourmat) to 
induce cross-linking of tU nucleotides to RNA. Total 
RNA was extracted adding TRIzol reagent (Thermo 
Fisher) directly on adherent cells and following the 
instructions provided by the manufacturer. After 
DNase treatment, 15 µg of RNA was incubated for 4 
hours at 4°C with 100 µl of streptavidin-conjugated 
beads (200 µl of Streptavidin Sepharose high 
performance, GE Healthcare) previously suspended 
in PO buffer (1M Tris pH8, 5M NaCl, 1M MgCl2, NP40 
50 µl in 100 ml buffer). After 2 washes with PO buffer 
and 2 washes with DEPC-treated water, the RNA 
complexed with beads was recovered by adding 1 ml 
Trizol directly on the beads followed by the TRIzol 
RNA extraction protocol. We performed two 
biological replicates obtaining two miR-26aCT 
(control) and two miR-26aBIO (miR-26a-5p) pull out 
samples 
Target Identification by Next Generation 
Sequencings (NGS) 
The RNA isolated after the miRNA pullout 
procedure from both miR-26aCT and miR-26aBIO 
samples was used for the construction of the cDNA 
libraries using the TruSeq Stranded Total RNA 
Sample Preparation kit (Illumina) according to the 
manufacturer’s suggestions. cDNA libraries were 
sequenced using the HiSeq2000 (Illumina) in 
single-reads mode (50bp) by IGA Technology Service, 
Udine, Italy, obtaining about 20 million reads for each 
sample.  
NGS data analysis 
NGS data (GEO accession number GSE85306) 
were analyzed using the Galaxy platform 
(https://usegalaxy.org/). Briefly, after quality control 
analysis (using FastQC) we made use of TopHat2 to 
align the reads on the human genome (version hg38). 
Then, the Cufflinks suite of tools was used to 
assemble transcripts and estimate their abundances. 
The final transcriptome assembly was obtained by 
using Cuffmerge. The differential expression analysis 
was performed using Cuffdiff. The differentially 
expressed transcripts with q-value < 0.05 were 
selected for downstream analyses.  
Bioinformatics analyses 
The available normalized log2 miRNA 
expression data of PCa patients were retrieved from 
cBioPortal (http://www.cbioportal.org/; GEO 
accession number: GSE21032). This dataset consists of 
99 primary and 14 metastatic tumor tissues and 27 
normal controls.  
In order to identify the miR-26a-5p predicted 
targets in the miR-26a-5p/targetome we used the 
following prediction algorithms: TargetScan 7 [15], 
PITA [16] and RNA22 [17]. The analyses were 
performed using the script versions of these 
programs. We considered for PITA and RNA22 a 
maximum of one mismatch and one G:U in the seed 
match. Moreover, RNA22 returned also a p-value and 
the folding energy for each miRNA-target interaction. 
We selected as cut-off a folding energy <= -10 and a 
p-value <= 0.05. For PITA we selected a score (i.e. the 
ddG score based on the folding energy) <= -10. A 
transcript was considered as putative target if at least 
one target prediction algorithm predicted the 
interaction. For these analyses, we predicted the 
miRNA binding sites in the 3’-UTR retrieving the 
sequences by UCSC Table Browser (http://genome. 
ucsc.edu/).  
The Gene Set Enrichment Analysis was 
performed using the GSEA online tool developed by 
the Broad Institute (http://software.broadinstitute 
.org/gsea/msigdb/index.jsp) using the MSigDB (the 
Molecular Signatures Database) as annotated gene 
sets. Significant terms (e.g. pathways) were 
considered using q < 0.05. 
The Protein-Protein Interaction Network (PPIN) 
was constructed using the StringApp, a Cytoscape 
app (http://www.cytoscape.org/) that is able to 
query the String database [18], a protein-protein 
interaction database. A medium confidence score of 
0.4 was used as minimum required interaction score. 
All the disconnected nodes in the network were 
removed, maintaining only the proteins with at least 
one interaction. 
The ClusterOne algorithm implemented in 
Cytoscape was used to find functional modules. The 
default parameters were used considering a minimum 
size of three proteins and the String confidence score 
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was used as edge weights for the clustering. 
Quantification of miRNAs and mRNAs 
(qRT-PCR) 
Total RNA was extracted from 1x106 cells using 
the miRNeasy mini kit following the manufacturer’s 
recommendations. 1µg of total RNA were retro 
transcribed using either the miScript II RT kit 
(Qiagen) or the QuantiTect reverse Transcription kit 
(Qiagen) for the miRNA or the mRNA quantification, 
respectively. The reverse transcription was made 
following the instructions given by the manufacturer. 
MiRNAs and the mRNAs were quantified with 
Rotor-Gene Q 2plex (Qiagen), using the miScript 
SYBR Green PCR Kit (Qiagen) or the SsoAdvanced ™ 
SYBR ® Green Supermix (Bio-Rad) respectively, 
according to the protocol indicated by the 
manufacturer. The relative quantification was 
performed using the Rotor-Gene Q Software, 
normalizing to the internal controls (U6, SNORD55 
and SNORD110 for miRNA and GAPDH, ACTB and 
HPRT for mRNA). The relative miR-26a-5p 
expression level in PCa tumor cell lines was evaluated 
respect to the normal prostate cells RNA (FirstChoice 
human prostate total RNA, Ambion). All reactions 
were performed in triplicate and the results are the 
mean of three biological replicates.  
Western Blot analysis 
Proteins were extracted from cell pellets with 
Lysis Buffer (1 M Tris HCl pH 8, Triton X 100 1%, Na 
deoxycholate 0.25%) with the addition of PMSF 1mM. 
The proteins were then quantified with colorimetric 
method using the Biorad protein Assay Reagent 
(Biorad). The absorbance was measured at 595 nm 
with ChroMate microplate reader (Awareness 
Technology). The proteins were separated on 
polyacrylamide gels SDS-PAGE (10% and 4-15 %, gel 
precast MINI-PROTEAN ® TGX Stain-FreeTM, 
BIO-RAD), and transferred to 0.2 µm nitrocellulose 
membranes by electro blotting using the Trans-Blot 
Turbo Blotting System (BIO-RAD). The resulting blots 
were blocked with 5% nonfat dry milk or BSA 
solution in TBST. Anti GAPDH (Cell Signaling) 
(1:10000) and anti BIRC5 (Santa Cruz Biotechnology) 
(1:100) primary antibodies were used. Incubation was 
performed overnight at 4°C and bands were revealed 
after incubation with the recommended secondary 
antibody coupled to peroxidase using ECL (GE 
Healthcare). Scanned images were quantified using 
ImageJ software and normalized to GAPDH. 
Luciferase Reporter Assay 
To verify the interaction of miR-26a-5p with 
BIRC5 gene, the sequence of the 3'UTR-BIRC5 was 
cloned downstream the luciferase coding sequence 
into the pmiR vector (pMIR-Report Luciferase, 
Ambion). HCT116 Dicer-/- colon cancer cells were 
seeded at density of 1,5x105 cells /well in a 12 well 
multiplate. The day after, cells were co-transfected 
using the Lipofectamine 2000 (Thermo Fisher) 
according to the manufacturer's instructions, with 150 
ng of pmiR-BIRC5 3'UTR, 100 ng of pRL control 
vector-TK (Renilla, Promega) and with 60 nM of 
ds-miR-26a-5p. The luciferase assay was performed 24 
hours after transfection, using Dual-Luciferase 
Reporter Assay System (Promega) and luminescence 
was evaluated by the luminometer GloMax-Multi 
Detection System, Promega). The pRL-TK (Renilla) 
was used to normalize the luminescence arising from 
pmiR-BIRC5 3' UTR construct. 
Statistical Analyses 
Results are expressed as mean SD of at least 
three independent experiments and data analysed by 
Student’s t-test (*P<0.05, **P<0.01, ***P<0.001). 
Results  
The re-expression of miR-26a-5p in prostate 
cancer cells 
A characteristic of TS-miRNAs is their under 
expression in either tumor tissues or tumor cell lines. 
Using the miRNA expression data from PCa patients 
of the cBioPortal database, we evaluated the 
miR-26a-5p expression in tumor tissues of patients 
with either primary or metastatic PCa. We found that 
miR-26a-5p tended to be under expressed in primary 
PCa and even more in metastatic PCa (Figure 1A), 
suggesting a positive relationship between the under 
expression and PCa tumor development. These data 
are in line with the recent literature in which the 
miR-26a-5p reduced expression was associated with 
metastasis and poor overall prognosis in PCa [6, 19]. 
We then quantified the expression of miR-26a-5p 
in both androgen independent (DU-145, PC3) and 
androgen dependent (22Rv1 and VCaP) prostate 
cancer (PCa) cell lines. Data clearly demonstrated that 
the miR-26a-5p was downregulated in all the 
analyzed tumor cell lines (Figure 1B).  
To detect the effects induced by the miR-26a-5p 
re-expression, we transfected miR-26a-5p in DU-145 
cells and analyzed a series of cell proliferation-related 
events. We showed that the miR-26a-5p exerted an 
anti-proliferative effect (Figure 2A) acting at several 
levels, by decreasing survival (Figure 2B) and 
inducing both cell cycle block (Figure 2C) and 
apoptosis (Figure 2D). Moreover, the miR-26a-5p 
re-expression impaired the capability of tumor cell to 
migrate (Figure 2E).  
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Figure 1. Relative quantification of miR-26a-5p expression level in tumor cell lines. (A) Analysis of the miR-26a-5p expression level data retrieved from 
the cBioPortal database. (B) qRT-PCR of miR-26a-5p in prostate (PC3, DU-145, VCaP, 22Rv1) cancer cell lines respect to the normal prostate cells RNA. Data are 
reported as mean of at least three independent experiments (*P<0.05, **P<0.01, ***P<0.001, unpaired t-test). 
 
Identification and validation of the 
miR-26a-5p/targetome 
Since a single miRNA targets hundreds of 
mRNAs, we searched for the genes which were 
affected by miR-26a-5p re-expression. We transfected 
DU-145 cells with miR-26a-5p and then performed the 
miRNA pull out protocol [14, 20, 21] adequately 
revised. The repertoire of the mRNAs linked with 
miR-26a-5p was collected and then the transcripts of 
the miR-26a-5p pull out sample identified using NGS. 
The miR-26a-5p/targetome consisting of 1423 
transcripts (1352 protein coding and 71 non-coding 
RNA) was obtained (Supplementary Table S1). To 
evaluate whether the miR-26a-5p/targetome 
contained miR-26a-5p targets, the 1352 protein coding 
transcripts were examined using three different 
miRNA-target prediction algorithms (TargetScan 7, 
PITA and RNA22). We found that 628 out of 1352 
transcripts (46%) were miR-26a-5p predicted targets 
(Supplementary Table S2) and 73 of them were also 
miR-26a-5p validated targets (based on miRTarbase, 
the database of experimentally validated miRNA 
targets [22] closure (Supplementary Table S3). These 
results suggested that the miRNA pullout assay was a 
fruitful method to capture reliable mRNA targets. 
Finally, we ranked the 628 transcripts according to the 
fold change of enrichment and 9 transcripts with 
different fold change value were selected. The 
qRT-PCRs confirmed the NGS expression data (Figure 
3A) and this led to be confident about the reliability of 
the miR-26a-5p targets identification. 
The miR-26a-5p regulatory networks 
We explored whether the miR-26a-5p/targetome 
represents a useful platform to discover the 
miR-26a-5p-dependent gene regulation networks. We 
used the GSEA tool on the 628 miR-26a-5p targets and 
22 significantly enriched pathways (q<0.05) were 
identified (Figure 3B). The majority of the pathways 
identified with this method were biological processes 
fundamental for cancer development (e.g. cell cycle) 
or pathways strictly correlated with cancer biology 
(e.g. MAPK, p53 and wnt signaling). Excluding 
endocytosis, the pathway in which the highest 
number of miR-26a-5p targets were involved was the 
“Pathway in cancer”. Among these targets, there were 
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EGFR and BIRC5 (Supplementary Table S4), which 
are involved in several aspects of cancer biology [23, 
24]. Although the validation of the pathways was 
outside of the aims of this work, we made an attempt 
in this direction by investigating the role played by 
BIRC5 (survivin) in prostate tumor cells. We verified 
that BIRC5 was downregulated (only at 
post-transcriptional level) in DU-145 cells transfected 
with miR-26a-5p (Figure 4A) and then demonstrated 
that BIRC5 was a miR-26a-5p direct target (Figure 4B). 
We then investigated if BIRC5 per se had a role in 
prostate cancer cells. We silenced BIRC5 in DU-145 
(Figure 4C) and we observed the reduction of cell 
proliferation and cell survival (Figure 4D) whereas 
apoptosis (Figure 4D), cell cycle (Figure 4E) and cell 
migration (Figure 4F) were unmodified.  
 
 
Figure 2. Effects of miR-26a-5p re-expression. The re-expression of miR-26a-5p reduced cell proliferation (A), decreased survival (B), induced a cell cycle 
block (C) and apoptosis (D) and impaired the cell migration (E). Data are reported as mean of at least three independent experiments (*P<0.05, **P<0.01, 
***P<0.001, unpaired t-test). 
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Figure 3. miR-26a-5p/targetome analysis. (A) Relative quantification with qRT-PCR of selected transcripts of miR-26a-5p/targetome in miR-26a-5p versus 
control pull out samples. Data are reported as mean of at least three independent experiments (*P<0.05, **P<0.01, ***P<0.001, unpaired t-test). (B) Result of the 
GSEA tool reporting the most significant KEGG pathways. In the Y axis we report each pathway with the q-value and in the X axis we report the number of genes 
in each pathway.  
 
Finally, we explored the Protein-Protein 
Interaction Network (PPIN) of the 628 miR-26a-5p 
targets and then extracted subnetworks of highly 
connected proteins in order to understand whether 
miR-26a-5p was able to regulate functional modules. 
We obtained a large network of 450 proteins and 956 
interactions where at least one protein was connected 
to another one (Supplementary Table S5). Then, using 
a clustering algorithm we extracted 20 significant 
modules (p<0.05, Table 1), suggesting that miR-26a-5p 
can interact with several targets within the same 
module regulating multiple functions. The obtained 
modules involved proteins that may play a role in 
cancer. In particular, the most significant module 
(p=0.003) included six proteins (Figure 5) some of 
which have already been studied in the context of 
tumor biology. For instance, DDX, an RNA helicase 
whose family is often deregulated in cancer [25] and 
GNL3L, which is involved in cell cycle regulation [26] 
and overexpressed in tumor cells that exhibit markers 
and tumorigenic properties of the tumor initiating 
cells (TICs) [27].  
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Figure 4. Validation of miR-26a-5p/BIRC5 interaction and BIRC5 function in prostate cancer. Relative quantification of BIRC5 expression level at both 
transcriptional (by qRT-PCR) and translational (by western blot) levels after BIRC5 silencing (A) and miR-26a-5p overexpression (C) in DU-145 cells. (B) Relative 
Luciferase activity after the cotransfection of pmiR-BIRC5 3’ UTR and either miR-26a-5p or miR-CT. Cell proliferation, survival, apoptosis (D), cell cycle (E) and cell 
migration (F) in DU-145 cells after BIRC5 silencing. Data are reported as mean of at least three independent experiments (*P<0.05, **P<0.01, ***P<0.001, unpaired 
t-test). 
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Table 1. Network analysis of miR-26a-5p targets. 
Clusters Number of proteins Proteins in modules p-value 
C1 6 DDX21, DDX54, MDN1, GNL3L, NAT10, DDX18 0.002537434 
C2 7 DDX23, HNRNPA3, SRSF11, NUP214, CPSF2, ZC3H4, NUP210 0.00364518 
C3 11 CARM1, TBL1XR1, ABCA1, SREBF2, CEBPA, CROT, SOAT1, MED20, MED29, MED28, MED6 0.005176176 
C4 9 RAB3IP, STX6, RAB3B, SEPT11, STX2, RAB35, RAB3D, STX3, YKT6 0.008559119 
C5 5 AGPAT6, AGPAT3, MBOAT1, PISD, ADPRM 0.010785874 
C6 9 RAB3IP, STX6, RAB3B, STX2, RAB35, RAB3D, STX3, YKT6, TXLNA 0.010808197 
C7 9 DDX23, HNRNPA3, SRSF11, NUP214, CPSF2, HDAC4, IFRD1, ZC3H4, NUP210 0.013479035 
C8 4 GDAP1, MFN2, ZCCHC11, SMCR7L 0.014700525 
C9 4 EXOSC6, EXOSC2, NAA38, PATL1 0.014700525 
C10 4 GALNT7, B3GNT2, B4GALT1, SLC35D1 0.015191412 
C11 5 TMEM43, WNK3, SLC12A4, STK39, DSC2 0.018356928 
C12 4 CYLD, TRIM25, DDX58, TRIM56 0.027257239 
C13 4 WNK3, SLC12A4, FAM120C, STK39 0.030300985 
C14 3 C19orf54, ZDHHC8, SLC25A30 0.031801285 
C15 6 TAB2, CYLD, TRIM25, DDX58, BIRC2, TRAF5 0.03277608 
C16 3 ARSJ, ARSI, ARSA 0.03826125 
C17 3 RAB11FIP5, EHD1, RAB11FIP1 0.03826125 
C18 3 MTHFR, AHCYL2, ENO2 0.040427799 
C19 5 CELSR2, VANGL2, RYK, CELSR1, WNT7B 0.04684631 
C20 12 INPP5B, ARHGEF7, PARD6B, CYFIP1, RND2, PLEKHG2, RHOBTB3, PLEKHG4B, RHOQ, OPHN1, 
CDC42EP3, RHOB 
0.049791258 
 
 
 
 
Figure 5. Protein-protein interaction analysis. The most significant 
cluster obtained by using the ClusterOne algorithm on the Protein-Protein 
Interaction network of miR-26a-5p targets. 
 
Discussion 
MiRNAs are involved in a variety of biological 
processes and their deregulation may be associated 
with the genesis of various diseases, including cancer 
[28]. Many studies have shown that some miRNAs, 
defined onco-miRNAs, inhibit TS gene expression 
while other miRNAs, defined TS-miRNAs, are 
capable to inhibit oncogenes. TS-miRNAs are often 
under-expressed in tumors [29] thus presuming a 
causal association between the under expression of 
TS-miRNAs and tumor development. The current 
interest in studying the replacement of TS-miRNA 
derives from two observations: miRNAs are globally 
under-expressed in cancer [30] and the replacement of 
TS-miRNAs to physiological levels was evaluated as 
an effective therapeutic approach in vivo [31]. The 
identification of the genes affected by the 
re-expression of miR-26a-5p could allow deciphering 
the TS activity of miR-26a-5p. We have isolated 
miR-26a-5p targets using the miRNA pull out assay, a 
technique that, unlike other computational and 
experimental approaches, allowed the isolation of 
mRNA targets of a specific miRNA in a determined 
cellular context. The expression profiles of the 
captured transcripts performed with NGS technology 
allowed the identification of 1423 differentially 
expressed transcripts, 1352 transcripts coding and 71 
transcripts non-coding sequences. Most of the 71 
non-coding transcripts belong to categories of RNA 
with known regulatory function (lincRNAs, 
pseudogenes, antisense RNAs and miRNA 
precursors). In addition, for some of them an 
involvement in the tumor biology has been already 
demonstrated: e.g. SNHG16 (Small Nucleolar Host 
RNA Gene 16) is a long non-coding RNA that has 
been associated with the development and the 
invasiveness of bladder cancer [5]. This observation 
suggests that the regulation of the expression of the 
non-coding RNAs may play a role in the 
anti-proliferative activity of miR-26a-5p. Therefore, 
the identified non-coding RNAs may represent novel 
candidates suitable for investigation as molecules 
with a potential role in cancer development. 
We used three algorithms based on different 
approaches to evaluate the enrichment of the coding 
portion of the miR-26a-5p/targetome of miR-26a-5p 
predicted targets. Particularly, we selected TargetScan 
7, PITA and RNA22 to take into consideration both 
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canonical and non-canonical miRNA/targets 
interaction because a large number of miRNAs 
interact with their targets through this type of 
interaction [13]. The result of our analysis was that 
about 46% of the identified transcripts were 
miR-26a-5p predicted targets indicating that the 
miR-26a-5p/targetome was significantly enriched of 
miR-26a-5p targets.  
We also showed that the predicted targets were 
part of pathways relevant to cancer. Using GSEA we 
identified 22 KEGG pathways, the majority of which 
are fundamental or directly associated with cancer 
progression and/or biology. This result underlines 
the fact that the availability of miR-26a-5p/targetome 
is a useful platform to discover the gene networks that 
play a relevant role in the miRNAs function. For 
instance, among the KEGG pathways comprising the 
largest number of targets, we selected “Pathway in 
cancer”. The genes belonging to this pathway would 
be relevant for tumorigenesis and, as proof of 
principle, we focused on BIRC5, a multifunctional 
protein that participates in the cell cycle control, 
apoptosis and response to DNA damage in tumor 
cells [24, 32]. Data showing that the silencing of BIRC5 
causes a decrease of cell proliferation both in vitro and 
in vivo have been also reported [33, 34]. Moreover, 
high BIRC5 expression is related to a higher Gleason 
score [35] as well as with clinic-pathological features 
of aggressive PCa [36, 37]. 
We demonstrated that miR-26a-5p directly 
regulated BIRC5 expression in DU-145 cells and that 
the BIRC5 silencing reduced cell proliferation and 
survival without affecting cell cycle, apoptosis and 
migration. As BIRC5 alone influenced only some of 
the biological effects induced by miR-26a-5p, the 
validation of more elements of each pathway rather 
than a single gene must be pursued. 
Finally, by using the Protein-Protein Interaction 
Networks we discovered that a large number of the 
miR-26a-5p targets coding for proteins functional 
connected each other, suggesting that miR-26a-5p 
regulation is mediated by the repression of more than 
one gene involved in the same process. It is of note 
that some members of the most significant modules of 
functional related proteins have been already 
associated to cancer [25, 27]. 
In conclusion, we demonstrated that the 
re-expression of miR-26a-5p in DU-145 prostate tumor 
cells reduced the proliferation indicating that 
miR-26a-5p tumor suppressor activity was restored. 
Moreover, we showed that the analysis of the 
transcripts interacting with miR-26a-5p 
(miR-26a-5p/targetome) with specific bioinformatics 
tools allowed the identification of genes and gene 
expression networks regulated by miR-26a-5p. In 
particular, the most relevant output of this work was 
the identification of several genes and pathways 
affected by miR-26a-5p regulation with a possible role 
in PCa. Therefore, an increasing availability of 
miRNA-specific and tumor-specific targetomes will 
increase the probability to find out genes and 
pathways related to cancer development/progression 
regulated by miRNAs. In the future, we will 
investigate more in detail the effect of miR-26a-5p 
regulation on pathway/s relevant for cancer and in 
which more than one miR-26a-5p targets are involved 
both in vitro and in a xenograft model. Moreover, to 
evaluate the clinical relevance of the above-mentioned 
target/s in PCa, we will investigate their expression, 
together with miR-26a-5p expression, in biopsy and 
normal tissues from prostate cancer patients with 
primary or metastatic tumor, as well as their possible 
correlation with parameters of tumor aggressiveness.  
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